IO Biotech, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 26.18 million compared to USD 20.07 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.7 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | -0.75% | -5.71% | -29.79% |
May. 15 | HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating | MT |
May. 14 | IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.79% | 87.62M | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- IOBT Stock
- News IO Biotech, Inc.
- IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023